Press release
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second
About this update from Insmed Incorporated
[{"type":"text","content":"—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023—\n—U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024—\n—Primary Endpoint for ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Infection Agreed Upon with U.S. FDA—\n—Company Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023—\nBRIDGEWATER, N.J., Aug. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.\n\"The second quarter of 2024 marked a pivotal moment in Insmed's history with positive topline data from the landmark Phase 3 ASPEN study. We were thrilled to deliver such promising news to the bronchiectasis community and to join them in celebrating these groundbreaking and long-awaited results,\" said Will Lewis, Chair and Chief Executive Officer of Insmed. \"Our focus now is on moving rapidly toward filing for regulatory approval of brensocatib and preparing to execute flawlessly on our commercial launches around the world, beginning in the U.S. in mid-2025, if approved. Behind these efforts, I am proud of how we are advancing other aspects of our business, including delivering our strongest quarter yet for ARIKAYCE with double-digit growth in our three commercial regions. We have a tremendous opportunity ahead and are excited to continue progressing toward the vision we set out for this company over a decade ago.\"\nRecent Pillar Highlights \nPillar 1: ARIKAYCE \nARIKAYCE global revenue grew 17% in the second quarter of 2024 compared to the second quarter of 2023, reflecting double-digit year-over-year growth in the U.S., Japan, and Europe and all-time revenue highs for each of these three regions.The Company met with the U.S. Food and Drug Administration (FDA) in June and aligned on the primary endpoint for the Phase 3 ENCORE study in patients with newly diagnosed or recurrent Mycobac...